ClinicalTrials.gg
RecruitingNCT07048951CONSCIOUS-ICUUpdated Jul 3, 2025

Episodes of (Dis)Connected Consciousness in ICU Survivors

An observational study in Consciousness, Near Death Experience and ICU, sponsored by University of Liege. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by University of Liege · Observational

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Study summary

This single-center observational study aims to describe the incidence of episodes of connected consciousness and disconnected consciousness (including near-death experience (NDE) and out-of-body experiences) in patients who survived a prolonged stay of at least 7 days in the intensive care unit (ICU) and who had at least one episode of pharmacological or non-pharmacological coma. The investigators are also investigating the risk factors related to these episodes of consciousness. A follow-up at six months aims to explore the long-term psychological implications of these episodes.

02

Conditions studied

  • Consciousness
  • Near Death Experience
  • ICU
  • Critical Illness

Keywords

  • near-death experience
  • out-of-body experience
03

In context

Death

456 studies on the registry are indexed under Death; 86 are open to participants now.

This study's planned enrollment of 200 is below the median of 400 across 236 observational studies indexed under Death.

Browse Death studies →

Lead sponsor

University of Liege is the lead sponsor of 251 studies on the registry; 50 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All adult patients admitted in the ICU

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients who survived a ≥7 days stay in the intensive care unit
  • Experienced a pharmacological or non-pharmacological episode of loss of consciousness
  • French speaking

Exclusion criteria

Exclusion Criteria:

  • Refusal
  • Chronic disorder of consciousness
  • Confusion or delirium
  • Deafness
  • Blindness
  • Aphasia
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Survivors of prolonged ICU (≥7days) stay with episode(s) of pharmacological/non-pharmacological coma

    Diagnostic Test: The Near-Death Experience Content (NDE-C) scale · Other: Threat perception measure · Other: Interview about the participant's memories of the ICU

Interventions

  • Diagnostic testThe Near-Death Experience Content (NDE-C) scale

    Questionnaire to detect occurence of NDE. A NDE is identified if score \> or = 27/80

  • OtherThreat perception measure

    7 items scale investigating the participant's psychological vulnerability during their stay at the ICU

  • OtherInterview about the participant's memories of the ICU

    Participants will be asked to describe any dream, hallucination, or any other unusual experience they can recall from their stay at the ICU. Additionally, the participants will be asked to describe any memory they have of the environment of the ICU, such as the appearance of the room, medical staff, family visiting, noises, etc.

06

What researchers measure

Primary outcomes

  1. Detection of potential episodes of disconnected consciousness

    Near-death experience (using the Near-Death Experience Content scale, min-max: 0-80, with ≥27/80 indicating the presence of a NDE); dream

    Time frame: Within the week following discharge from the ICU (max 7 days after)

  2. Detection of potential episodes of connected consciousness

    Explicit recall of environmental/external stimuli in the ICU

    Time frame: Within the week following discharge from the ICU (max 7 days after)

Secondary outcomes

  1. Risk factors

    (Neuro)physiological marker

    Time frame: Within the week following discharge from the ICU (max 7 days after)

  2. Psychological vulnerability during the stay at the ICU

    Using the Threat Perception Measure, a scale that contains 7 items related to feelings and anxieties perceived by the patient, each scored from 1 to 4, ranging from 1 "Not at all", 2 "A little", 3 "Moderately", and 4 "Extremely", as well as a "don 't remember" category. Min-max: 7-28, with higher scores indicating a higher level of perceived threat

    Time frame: Within the week following discharge from the ICU (max 7 days after)

  3. Psychological impact of the stay at the ICU

    Any patient who stayed at least 7 days at the ICU is invited to a 6 month follow-up during which they will be presented Hospital Anxiety and Depression Scale (HADS, min-max: 0-42, with higher scores indicating a worse outcome, i.e., more severe symptoms of anxiety or depression), to assess anxiety and depression as well as the Post-Traumatic Stress Assessment Questionnaire (IES-R, min-max: 0-88, with higher scores indicating a worse outcome, i.e., more severe post-traumatic stress symptoms). The investigators will be asking two additional questions to investigate a possible impact on the patient's beliefs. * Question 1: "Since your stay in intensive care, have your beliefs/opinions changed regarding death?". * Question 2: "Has your stay in intensive care modified your fear of health care institutions?

    Time frame: At a 6 month follow-up after discharge from the ICU

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jan 2027, 21 months after the start.

Of 84 non-industry observational studies under Death, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 245. This study's planned 21 months is below that.

Counting every sponsor, half of 87 studies reached it within 60 months; a quarter within 23 and three quarters within 245.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2025
First posted
Jul 3, 2025
StartActual
Apr 1, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Apr 2027
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07048951
Collaborators
Centre Hospitalier Universitaire de Liege
Responsible party
Sponsor
First posted
Jul 3, 2025
Start date
Apr 1, 2025
Primary completion
Jan 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Jul 3, 2025

Study contacts

Charlotte Martial, PhD
Contact
cmartial@uliege.be
+3243233612

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion